{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:04:15Z","timestamp":1790690655876,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bneo.2026.100234","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T16:11:29Z","timestamp":1776269489000},"page":"100234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world pharmacokinetics of venetoclax in patients with acute myeloid leukemia in Japan"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0035-8657","authenticated-orcid":false,"given":"Minoru","family":"Kanaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5662-0418","authenticated-orcid":false,"given":"Yuji","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goichi","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7340-5277","authenticated-orcid":false,"given":"Mirei","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Kajikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3810-4488","authenticated-orcid":false,"given":"Toma","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3592-9066","authenticated-orcid":false,"given":"Shinpei","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8817-7107","authenticated-orcid":false,"given":"Takashi","family":"Ishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1207-2138","authenticated-orcid":false,"given":"Emi","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0762-6255","authenticated-orcid":false,"given":"Koh","family":"Izumiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Morioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2064-2145","authenticated-orcid":false,"given":"Akio","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-3778","authenticated-orcid":false,"given":"Toshihiro","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Onozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Moriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5725-7187","authenticated-orcid":false,"given":"SungGi","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0941-271X","authenticated-orcid":false,"given":"Takanori","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-0739","authenticated-orcid":false,"given":"Yosuke","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4824-3242","authenticated-orcid":false,"given":"Masato","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bneo.2026.100234_bib1","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1080\/10428194.2021.2002321","article-title":"Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy","volume":"63","author":"Miyamoto","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.bneo.2026.100234_bib2","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000912","article-title":"BCL2 inhibition: a new paradigm for the treatment of AML and beyond","volume":"7","author":"Wei","year":"2023","journal-title":"Hemasphere"},{"issue":"7","key":"10.1016\/j.bneo.2026.100234_bib3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.bneo.2026.100234_bib4","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2026.100234_bib5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00277-023-05102-y","article-title":"Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia","volume":"102","author":"Aiba","year":"2023","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.bneo.2026.100234_bib6","doi-asserted-by":"crossref","first-page":"E63","DOI":"10.1002\/ajh.27180","article-title":"Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: comparative analysis of response, toxicity, and survival","volume":"99","author":"Karrar","year":"2024","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100234_bib7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41408-025-01324-7","article-title":"Comparable outcomes with 14-21-or standard 28-day venetoclax in the first cycle of azacitidine\u2013venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net","volume":"15","author":"Kanaya","year":"2025","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.bneo.2026.100234_bib8","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/hon.2964","article-title":"Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-na\u00efve acute myeloid leukemia who are ineligible for intensive chemotherapy","volume":"40","author":"Brackman","year":"2022","journal-title":"Hematol Oncol"},{"issue":"4","key":"10.1016\/j.bneo.2026.100234_bib9","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/ajh.27613","article-title":"Prospective pharmacokinetic evaluation of venetoclax in AML supports re-evaluation of recommended dose adjustments with azole antifungals","volume":"100","author":"Kawedia","year":"2025","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.bneo.2026.100234_bib10","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00280-024-04673-5","article-title":"Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia","volume":"94","author":"Kobayashi","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"issue":"14","key":"10.1016\/j.bneo.2026.100234_bib11","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1002\/cncr.33508","article-title":"Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia","volume":"127","author":"Rausch","year":"2021","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.bneo.2026.100234_bib12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clin Ther"},{"issue":"12","key":"10.1016\/j.bneo.2026.100234_bib13","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.2024024009","article-title":"How I treat patients with AML using azacitidine and venetoclax","volume":"145","author":"Wei","year":"2025","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bneo.2026.100234_bib14","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2026.100234_bib15","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.bneo.2026.100234_bib16","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1124\/dmd.116.071613","article-title":"Metabolism and disposition of a novel B-cell lymphoma-2 inhibitor venetoclax in humans and characterization of its unusual metabolites","volume":"45","author":"Liu","year":"2017","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.bneo.2026.100234_bib17","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/cts.13144","article-title":"A microdosing framework for absolute bioavailability assessment of poorly soluble drugs: a case study on cold-labeled venetoclax, from chemistry to the clinic","volume":"15","author":"Alaarg","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"3","key":"10.1016\/j.bneo.2026.100234_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100017","article-title":"Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS","volume":"1","author":"Othman","year":"2024","journal-title":"Blood Neoplasia"},{"issue":"2","key":"10.1016\/j.bneo.2026.100234_bib19","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1586\/ecp.10.143","article-title":"Modeling and predicting drug pharmacokinetics in patients with renal impairment","volume":"4","author":"Rowland Yeo","year":"2011","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.bneo.2026.100234_bib20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/cc7093","article-title":"Clinical review: drug metabolism and nonrenal clearance in acute kidney injury","volume":"12","author":"Vilay","year":"2008","journal-title":"Crit Care"},{"issue":"1","key":"10.1016\/j.bneo.2026.100234_bib21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/cpt.337","article-title":"Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4\/5","volume":"100","author":"Yoshida","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.bneo.2026.100234_bib22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bneo.2026.100234_bib23","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.bneo.2026.100234_bib24","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/jcph.821","article-title":"Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin lymphoma","volume":"57","author":"Salem","year":"2017","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.bneo.2026.100234_bib25","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1080\/10428194.2025.2519921","article-title":"Comparable response rates of venetoclax 50 mg with posaconazole versus venetoclax 400 mg despite lower pharmacokinetic exposure in newly diagnosed acute myeloid leukemia: less is enough","volume":"66","author":"Swain","year":"2025","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"10.1016\/j.bneo.2026.100234_bib26","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2026.100234_bib27","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/bjh.19292","article-title":"Novel stratification for newly diagnosed acute myeloid leukemia treated with venetoclax-based therapy in the real world: Hokkaido Leukemia Net Study","volume":"204","author":"Miyashita","year":"2024","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.bneo.2026.100234_bib28","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41375-024-02501-6","article-title":"A novel prognostic risk model for patients with refractory\/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents","volume":"39","author":"Shahswar","year":"2025","journal-title":"Leukemia"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:16:48Z","timestamp":1790687808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2950328026000452"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100234","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world pharmacokinetics of venetoclax in patients with acute myeloid leukemia in Japan","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100234","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100234"}}